Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

The Vulnerable Phase of Heart Failure

Gracia, Ely MD1; Singh, Prabhjot MD2; Collins, Sean MD3; Chioncel, Ovidiu MD4; Pang, Peter MD5; Butler, Javed MD, MPH, MBA*,6

doi: 10.1097/MJT.0000000000000794
Mihai Gheorghiade Memorial Symposium

1Department of Internal Medicine, Stony Brook University Hospital, Stony Brook, NY;

2Department of Cardiology, Stony Brook University Hospital, Stony Brook, NY;

3Department of Emergency Medicine, Vanderbilt University, Nashville, TN;

4Department of Cardiology, University of Medicine Carol Davila, Bucuresti; Institute of Emergency for Cardiovascular Diseases “Prof C.C.Iliescu,” Bucharest, Romania;

5Department of Emergency Medicine and Indianapolis EMS, Indiana University School of Medicine, Indianapolis, IN; and

6Department of Medicine, University of Mississippi School of Medicine, Jackson, MI.

Address for correspondence: Department of Medicine, University of Mississippi School of Medicine, 2500 North State St, Jackson, MI 39216. E-mail:

S. P. Collins research funding from NIH, AHRQ, PCORI and consulting funding from Medtronic and Novartis. O. Chioncel reports grants from Servier, grants from Vifor, grants from Novartis. P. S. Pang is or has been in the last one year a consultant for Baxter, BMS, Novartis, and Roche Diagnostics and has received research or other support from BMS, Roche, Novartis, PCORI, AHA, NHLBI, AHRQ. J. Butler has received research support from the NIH, PCORI, and the European Union; and serves as a consultant for Amgen, Array, Astra Zeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squib, CVRx, G3 Pharmaceutical, Innolife, Janssen, Luitpold, Medtronic, Merck, Novartis, Relypsa, StealthPeptide, SC Pharma, Vifor, and ZS Pharma. The remaining authors have no conflicts of interest to declare.

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.